Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-18-906 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Notice Number: NOT-NS-20-023

Key Dates
Release Date: March 3, 2020
First Available Due Date: April 15, 2020
Expiration Date: June 30, 2020

Related Announcements
PA-18-906 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Center for Complementary and Integrative Health (NCCIH)

National Center for Advancing Translational Sciences (NCATS)

National Cancer Institute (NCI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)


The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see the recently funded NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by enhancing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-18-906, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at:

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-18-906 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and PA-18-906 must be followed, with the following additions:

  • Application Due Date(s) – April 15, 2020 and June 1, 2020 by 5:00 PM local time of applicant organization.
  • For funding consideration, applicants must include “NOT-NS-20-023” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
  • The Research Strategy section of the application is limited to 6 pages.
  • Only existing awardees of the HEAL Initiative program are eligible to apply.
  • The process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.
  • Applicants are strongly encouraged to notify the program contact at the Institute supporting the parent award as well as that a request has been submitted in response to this FOA in order to facilitate efficient processing of the request.
  • As the first sentence of the Research Strategy, applicants are requested to state that the parent grant was awarded as a HEAL Initiative award and to identify the specific FOA of the parent grant (e.g., RFA-NS-19-016) to facilitate processing of the supplement application.
  • HEAL diversity supplement awardees are strongly encouraged to participate in annual PD/PI meetings and in other activities with their mentors. Applicants may request funds, in addition to the research costs specified in PA-18-906, to enable the supplement candidate to attend the annual HEAL Initiative PD/PI meeting in the Washington, DC area. This request for additional funds should be reasonable and well justified in the application.
  • Potential applicants are strongly encouraged to review the supplemental guidance for diversity supplement applications on the NINDS web site. Consultation with the Program Official for the qualifying HEAL award or the individual named under Inquiries below is highly recommended.
  • Supplement applications will be evaluated by the HEAL Initiative diversity committee.

Applications non-responsive to terms of this NOSI will be not be considered for the NOSI initiative.


Please direct all inquiries to:

Eric Hudak, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779